Daiwa Capital Markets assumed coverage on shares of Legend Biotech (NASDAQ:LEGN – Get Rating) in a report published on Monday, The Fly reports. The firm issued a buy rating on the stock. A number of other analysts have also recently commented on the company. Morgan Stanley boosted their price objective on Legend Biotech from $60.00 […]
Research analysts at Daiwa Capital Markets began coverage on shares of Legend Biotech (NASDAQ:LEGN – Get Rating) in a research note issued to investors on Monday, The Fly reports. The brokerage set a “buy” rating on the stock. Other analysts have also issued research reports about the company. JPMorgan Chase & Co. increased their price […]
Legend Biotech (NASDAQ:LEGN – Get Rating) had its price objective boosted by Barclays from $65.00 to $90.00 in a research note released on Friday, The Fly reports. Several other brokerages have also issued reports on LEGN. BTIG Research raised their target price on Legend Biotech from $75.00 to $85.00 and gave the company a buy […]
Legend Biotech (NASDAQ:LEGN – Get Rating) had its price objective boosted by research analysts at Royal Bank of Canada from $74.00 to $83.00 in a research note issued to investors on Friday, The Fly reports. Royal Bank of Canada’s price target suggests a potential upside of 18.42% from the stock’s current price. Other equities analysts […]
TimesSquare Capital Management LLC grew its position in shares of Legend Biotech Co. (NASDAQ:LEGN – Get Rating) by 0.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 946,500 shares of the company’s stock after buying an additional 5,200 shares during the quarter. […]